Infectious Bronchitis Virus - Variant D274 antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Infectious Bronchitis Virus - Variant D274 antibodies pairs and antigen for animal health (animal Chicken infectious disease respiratory disease) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Avian/Bird/Poultry disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P152-Ag01	Recombinant Infectious Bronchitis Virus - Variant D274 protein	$3090.00
GMP-VT-P152-Ab01	Anti-Infectious Bronchitis Virus - Variant D274 mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P152-Ab02	Anti-Infectious Bronchitis Virus - Variant D274 mouse monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P152-Ag01
Product Name	Recombinant Infectious Bronchitis Virus - Variant D274 protein
Pathogen	Infectious Bronchitis Virus - Variant D274
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Infectious Bronchitis Virus - Variant D274 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Infectious Bronchitis Virus - Variant D274 level test of animal Chicken infectious disease with respiratory disease.
Tag	His
Product description	Recombinant Infectious Bronchitis Virus - Variant D274 proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P152-Ab01,GMP-VT-P152-Ab02
Pathogen	Infectious Bronchitis Virus - Variant D274
Product Name	Anti-Infectious Bronchitis Virus - Variant D274 mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Infectious Bronchitis Virus - Variant D274 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Infectious Bronchitis Virus - Variant D274 antibodies in Infectious Bronchitis Virus - Variant D274 level test of animal Chicken infectious disease with respiratory disease.
Product description	Anti-Infectious Bronchitis Virus - Variant D274 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Infectious Bronchitis Virus - Variant D274 antibodies./td>
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen

Infectious Bronchitis Virus (IBV) is a highly infectious respiratory pathogen that primarily affects chickens, leading to significant economic losses in the poultry industry worldwide. IBV belongs to the family Coronaviridae, which includes other human and animal coronaviruses such as SARS-CoV-2, MERS-CoV, and feline coronavirus.

The IBV genome is composed of a non-segmented, positive-sense, single-stranded RNA molecule of approximately 27 kilobases in length. It contains at least four major structural proteins, including the membrane (M), nucleocapsid (N), envelope (E), and spike (S) glycoproteins. Among these, the S glycoprotein is considered the most crucial for its role in host cell recognition, attachment, and membrane fusion. The S protein consists of two subunits, S1 and S2, with the former containing the RBD that interacts with host receptor proteins, and the latter responsible for membrane fusion. The S protein also harbors several immunogenic epitopes that stimulate the host immune response and contribute to vaccine design.

IBV exhibits a pleomorphic or egg-shaped structure, ranging from 80 to 200 nanometers in diameter. The virus is surrounded by a lipid envelope derived from the host cell membrane, within which the viral proteins are embedded. The S glycoprotein protrudes from the viral surface as spikes, giving IBV its characteristic crown-like appearance. The S protein is highly variable between different IBV strains or variants, due to frequent mutations, insertions, deletions, and recombination events. As a result, IBV displays high genetic diversity and antigenic variability, making it challenging to control the disease using conventional vaccination strategies.

IBV primarily infects the respiratory and urogenital tracts of susceptible chickens, although it can also invade other tissues such as the kidney, gut, and reproductive tract. The virus enters host cells via receptor-mediated endocytosis, using the S protein to bind to specific host receptor proteins such as peptidases or lectins. Once inside the cell, IBV releases its RNA genome, which serves as a template for viral replication and transcription. The resulting viral proteins and RNAs assemble into new virions, which are then released from the cell by budding or lysis, depending on the strain.

IBV infection in chickens can lead to a range of symptoms and clinical signs, depending on the virulence and tissue tropism of the infecting strain. Common respiratory signs include coughing, sneezing, nasal discharge, dyspnoea, and rales. These symptoms often result in decreased feed intake, weight gain, and egg production, leading to economic losses for farmers. In some cases, IBV can also cause mortality in young or immunocompromised birds, either directly or indirectly through secondary infections. Additionally, IBV can manifest as urinary or reproductive tract disease, affecting egg quality and hatchability.

Diagnosis of IBV infections typically involves a combination of clinical signs, serological assays, and molecular methods. Clinical signs alone may be insufficient to confirm IBV infection, as they can overlap with other respiratory pathogens. Serological assays such as enzyme-linked immunosorbent assay (ELISA) or virus neutralization test (VNT) can detect antibodies against IBV in blood samples, indicating exposure or immunity to the virus. However, these tests cannot discriminate between different IBV strains or variants. Molecular methods such as RT-PCR or loop-mediated isothermal amplification (LAMP) can detect and characterize IBV RNA in clinical samples, enabling strain identification and tracking. These methods often target conserved or variable regions of the IBV genome, such as the S gene, N gene, or P gene, and can be used for both research and diagnostic purposes.

In summary, IBV is a highly infectious respiratory pathogen that poses a significant threat to the poultry industry, causing respiratory and other related symptoms in chickens. The virus exhibits high genetic diversity and antigenic variability, making it challenging to control using traditional vaccination approaches. Diagnosis of IBV infections requires a combination of clinical signs, serological assays, and molecular methods, targeting different viral components such as the S protein or RNA genome. Further research is needed to better understand the pathogenesis, epidemiology, and evolution of IBV, as well as to develop more effective prevention and control strategies.

About GDU